uBiome Appoints Dr. Marie-Claire Arrieta, PhD, Microbiologist and Science Writer, to its Scientific Advisory Board

Share Article

The leader in microbial genomics appoints University of Calgary researcher to its board of scientific advisors.

“Microbiome science is revolutionizing the way we understand both communicable and noncommunicable human diseases. Although in its early stages, this new knowledge represents a new frontier in modern medicine.” - Dr. Arrieta, PhD

uBiome, the leader in microbial genomics, announces the addition of Dr. Marie-Claire Arrieta, PhD, Assistant Professor at the Cumming School of Medicine, University of Calgary, to its Scientific Advisory Board. Joining the board of leading scientists and doctors from around the world, Dr. Arrieta will bring to uBiome extensive study on role the of the intestinal microbiota in the development of immune-mediated and metabolic pediatric diseases, including inflammatory bowel disease (IBD) and asthma. The appointment will help uBiome continue its advancement in human microbiome research.

“Dr. Arrieta’s work sheds light on how the gut microbiome in one’s early years can shape one’s health later in life. The potential clinical applications for this field of study is immense,” Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. “We are honored to have Dr. Arrieta join the uBiome Scientific Advisory Board.”

Dr. Arrieta works within the Department of Pediatrics and Department of Physiology and Pharmacology at the Cumming School of Medicine at the University of Calgary. Her current research investigates how metabolites that originated from alterations in early-life intestinal microbiota contribute to intestinal and extraintestinal disease. Dr. Arrieta completed her PhD at the University of Alberta, where she explored the role of intestinal permeability in the pathogenesis of IBD. She is the author of the best-selling book, “Let Them Eat Dirt.”

About joining uBiome's Scientific Advisory Board, Dr. Arrieta said, “Microbiome science is revolutionizing the way we understand both communicable and noncommunicable human diseases. Although in its early stages, this new knowledge represents a new frontier in modern medicine. uBiome has assembled an impressive list of accomplished scientists as part of their Scientific Advisory Board, which I am honored to join.”

In addition to Dr. Arrieta, the uBiome Scientific Advisory Board also includes Dr. Joseph DeRisi (MacArthur Genius and UCSF professor), Dr. Atul Butte (head of the Institute for Computational Health Sciences at UCSF), Dr. Katherine Pollard (Director, Gladstone Institute for Data Science and Biotechnology), Dr. Joel Palefsky (UCSF School of Medicine professor), Dr. George Church (leading geneticist at Harvard University), Dr. Liz Lipski (Academic Director of Nutrition and Integrative Health Programs at Maryland University of Integrative Health), Dr. Elaine Hsiao, PhD (UCLA), and other leading scientists. The company’s Medical Advisory Board includes Dr. Alan Green (Society for Participatory Medicine), Dr. Leo Treyzon (Cedars-Sinai Medical Center), Dr. Cynthia Geyer (Medical Director of Canyon Ranch, Lenox), Dr. Robynne Chutkan (Georgetown University Hospital), Michael Docktor (Boston Children’s Hospital), Dr. Tiffany Lester (Medical Director of Parsley Health in San Francisco), Dr. Joel Kahn (Founder of of the Kahn Center for Cardiac Longevity), as well as other accomplished clinicians.

About uBiome
Founded in 2012, uBiome is the leader in microbial genomics. The Company’s mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets.

uBiome’s commercial products include SmartGut™, the world’s first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn’s Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women’s health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.

uBiome’s platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.

Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company’s Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

uBiome Public Relations
Visit website